A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

Erosive Esophagitis Clinical Trial

Official title:
A Randomized Double-blind, Double Dummy, Active Comparator-controlled Dose-finding Study in Patients With Erosive Esophagitis Due to Gastro-esophageal Reflux Disease (GERD) Los Angeles Grade C or D, and Patients With at Least Partial Symptom Response But Endoscopically Still Unhealed After 8 Weeks History of Standard Treatment Healing Course With Proton-pump Inhibitor (PPI), to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole, and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

Status Completed

Clinical Trial Summary

This study will be conducted in patients with erosive esophagitis due to gastro-esophageal reflux disease (GERD) Los Angeles (LA) grades C or D, and in patients with at least partial symptom response but still endoscopically unhealed (LA grades A or B) after 8 weeks history of standard treatment healing course with PPI, designed to support dose selection for Phase 3 and to investigate safety, tolerability, and healing rates after 4 weeks treatment of X842 or Lansoprazole, and symptom pattern during subsequent 4 weeks treatment with Lansoprazole.

Clinical Trial Description

This is a randomized, double-blind, active comparator-controlled study with a parallel-group design including four arms with X842 and one arm with Lansoprazole. Randomization to one of the treatments with X842 twice daily (BID) 25 mg, 50 mg, 75 mg, 100 mg, or Lansoprazole 30 mg once daily (QD) will be based on a 1:1:1:1:1 scheme. The duration of each patient's participation in the study, including screening, blind treatment period, and open-label treatment period will be approximately 60 days. The patients will be randomized for 4 weeks of double-blind treatment and will be provided with investigational medicinal product for 35 days. All patients will have an endoscopic evaluation after 4 weeks of treatment. Following the endoscopic evaluation, all patients will receive subsequent 4 weeks of open-label treatment with Lansoprazole. Repeated symptom evaluation to detect symptom patterns will be assessed during this period. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05055128
Study type	Interventional
Source	Cinclus Pharma AG
Contact
Status	Completed
Phase	Phase 2
Start date	August 11, 2021
Completion date	September 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01452776` - Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis	Phase 3
Recruiting	`NCT05587309` - A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis	Phase 3
Completed	`NCT04124926` - Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis	Phase 3
Completed	`NCT01459367` - Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis	Phase 3
Completed	`NCT00228527` - Esomeprazole for Treatment of GERD in Pediatric Patients	Phase 4
Completed	`NCT01499368` - A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients	Phase 3
Not yet recruiting	`NCT04613895` - Treatment Effect According to Timing of Administration of DWP14012 40 mg	N/A
Recruiting	`NCT02615184` - A Study of Dexlansoprazole in Healing and Maintenance of Healed Erosive Esophagitis (EE) in Children	Phase 2
Completed	`NCT02456935` - Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis	Phase 3
Completed	`NCT02028663` - Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis	Phase 2
Completed	`NCT03006874` - Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis	Phase 3
Completed	`NCT02388724` - Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis	Phase 3
Completed	`NCT01865825` - Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)?	N/A
Completed	`NCT02679508` - Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety	Phase 4
Recruiting	`NCT06391177` - A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily	Phase 1
Completed	`NCT05050188` - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008	Phase 1
Completed	`NCT01874535` - Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy	Phase 4
Completed	`NCT00206180` - NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis	Phase 4
Completed	`NCT01630746` - A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis	Phase 3
Completed	`NCT01642615` - Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents	Phase 2